Page 4 - Scientific Library

Extracellular adenosine 5'-triphosphate (ATP) is released by dying and damaged cells, and it acts on many immune

ADCC is a simple but important mechanism for the immune system to target diseased or infected cells. Antibodies bind to specific

Immunotherapy represents a field in Drug Discovery which is quickly developing and leading to significant progress in treatments of a number of diseases, especially cancer. The approach is based on inducing,

Today, I'd like to give you an overview about methods in actin research with validated R&D products and kits which will allow you to measure binding to actin and effects on the polymerisation dynamics

Protein biochemistry brings together a vast and varied world of methods of protein production, purification and characterization. Once you have successfully achieved the production of your protein in a

On your journey to Biomarker profiling, you will reach the point where you need to quantify the proteins of interest identified along the way (eg. validation of semi-quantitative

Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization

In a recent paper, Horita H. et al. identified a set of novel Post-Translational Modifications (PTMs) of the protein Programmed Cell Death Ligand (PD-L1).

Following the start of our recent collaboration with Phenocell, we’re pleased to be able to provide high quality Sebocytes developed from Human

Undoubtedly, producing and purifying a protein is an art form.

Indeed, each recombinant protein (rec. protein) to be produced in vitro

Use of validated antibodies is primordial for Breast Cancer research and related biomarker discovery. Here, we'll review the main biomarkers involved in this disease and introduce the

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab